Latest Administration News

Kingsland Minerals secures a $2.56 million strategic investment from Quinbrook Infrastructure Partners, marking a pivotal step in advancing the Leliyn Graphite Project with binding offtake and renewable energy agreements.

Highfield Resources progresses its strategic partnership with Yankuang Energy, securing key regulatory approvals and updating financing arrangements for the Muga Potash mine, while navigating a court ruling on a mining concession.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Charger Metals NL's December quarter cash flow report reveals a $800,000 net cash decrease, driven by sustained exploration spending and limited operating receipts, leaving the company with $2.49 million in cash.

Terra Uranium has significantly expanded its land holdings in the Athabasca Basin through strategic option agreements with ATHA Energy Corp, setting the stage for a robust 2025 drilling campaign amid a recovering uranium market.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

ioneer Ltd’s December 2024 quarterly cash flow report reveals ongoing cash outflows from operations and investing, with nearly $4.5 million spent this quarter but a solid cash reserve providing a runway of almost five quarters.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.